Research & Development
Hematology: Page 2
Quotient Q1 2023 revenues drop on customer order change
For the quarter ended June 30, the Eysins, Switzerland-based firm posted a net loss of $38.9 million, or $.37 per share, compared to $27.3 million, or $.27 per share, in fiscal Q1 2022.
August 8, 2022
Video from AACC: Beckman Coulter partners with Scopio
Dr. Peter Soltani, senior vice president and general manager at Beckman Coulter, and Itai Hayut, cofounder and CEO of Scopio Labs, spoke to LabPulse.com and ScienceBoard.net about the partnership.
July 31, 2022
Smartphone app, blood test may predict clotting risk
The test uses a smartphone's built-in vibration motor and camera to track movement of a copper particle in a drop of blood.
July 25, 2022
Beckman, Scopio to partner on blood smear platforms
Scopio's technology employs full-field imaging and artificial intelligence (AI) decision support with the aim of eliminating manual microscopy. The platform allows full-field images to be shared in real-time over a secure hospital network and captures large scan areas at 100X magnification.
July 19, 2022
Philips adopting proteomics results for patient management
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
Quotient discloses underwritten public offering price
The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.
June 23, 2022
Blood grouping, typing market estimated at $945 million
The overall market is expected to stabilize in 2022 and grow at a 1% compound annual growth rate (CAGR) through 2026 when revenues could reach $1 billion, according to the report, which is published by Kalorama Information, a sister publication of LabPulse.com.
June 16, 2022
PerkinElmer, Novartis expand newborn screening for SCD
In collaboration with the Novartis Africa Sickle Cell Disease program, PerkinElmer aims to expand advocacy efforts to educate patients, caregivers, and communities about the importance of newborn screening and early intervention with hydroxyurea and other SCD treatments.
June 15, 2022
FDA clears Scopio Labs hematology analysis platform
Tel Aviv, Israel-based Scopio said the X100HT is a full-field digital imaging and artificial intelligence (AI)-enabled platform that combines high throughput with high resolution for hematological analysis.
June 9, 2022
SeekIn receives CE Mark for karyotyping kit
Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.
April 6, 2022
PixCell signs MakGroup as distributor for the UAE
Dubai-based MakGroup will have exclusive distribution rights in the UAE for HemoScreen, a five-part, differential complete blood count analyzer that can provide results in five minutes, according to PixCell.
April 6, 2022
Revenues from coagulation lab and POC tests near $4B in 2021
Hemostasis (coagulation) is a complex process in which multiple enzymes and proteins regulate blood flow and clot formation. Coagulation (clot formation), fibrinolysis (the breakup of blood clots), and platelet aggregation are a part of this process.
February 15, 2022
Page 2 of 7